Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Next Previous
Trial Profile

A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/candesartan-cilexetil (Primary) ; Ezetimibe/rosuvastatin (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms REVERT-K
  • Sponsors HK inno.N

Most Recent Events

  • 09 May 2022 Status changed from active, no longer recruiting to completed.
  • 07 Jul 2021 Planned End Date changed from 5 Dec 2019 to 30 Nov 2021.
  • 07 Jul 2021 Planned primary completion date changed from 5 Nov 2019 to 30 Nov 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top